Minovia Therapeutics

Mitochondrial Augmentation Cell-therapy Platform

Health Tech & Life Sciences
Active
Public , Israel Founded 2011
Last updated 2026-06-18
Total raised
$28.4M
Last: Grant 2025-08
Stage
Public
Founded
2011
Headcount
26
HQ
, Israel
Sector
Health Tech & Life Sciences

About

Minovia Therapeutics treats mitochondrial diseases through cell therapy using its Mitochondrial Augmentation Therapy (MAT) platform. The companys initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments.

The company developed a cell therapy approach to treat a broad range of indications generated by a mitochondrial dysfunction. Using its proprietary Mitochondrial Augmentation Technology (MAT), designed to be a robust therapeutic platform combining personalized mitochondrial cell therapy and scalable manufacturing processes, Minovia is advancing breakthrough therapies for patients with mitochondrial dysfunction, caused by disease as well as during aging.

Minovia is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.

Funding history · 5 rounds · $28.4M total

2025-08
Grant $350K
2025-06
$18.0M
2025-01
Undisclosed
2021-02
Undisclosed
2018-12

Q&A

What is Minovia Therapeutics' primary focus?
Minovia Therapeutics focuses on treating mitochondrial diseases through cell therapy, utilizing its Mitochondrial Augmentation Therapy (MAT) platform. The company's initial clinical focus is on rare mitochondrial diseases that currently lack approved treatments.
When was Minovia Therapeutics founded?
Minovia Therapeutics was founded in December 2011.
What is the current employee count for Minovia Therapeutics?
Minovia Therapeutics has 11-50 employees.
What is Minovia Therapeutics' current clinical trial status?
Minovia Therapeutics is currently conducting a phase 1/2 clinical trial in patients with Pearson Syndrome.
When did Minovia Therapeutics go public?
Minovia Therapeutics went public on NASDAQ in June 2025.
Who led Minovia Therapeutics' funding round in December 2018?
The Yozma Group led Minovia Therapeutics' funding round in December 2018, which raised $10,000,000.
What was the most recent funding event for Minovia Therapeutics?
In August 2025, Minovia Therapeutics received a grant of $350,000.
What is the total amount of funding Minovia Therapeutics has raised to date?
Minovia Therapeutics has raised a total of $28,350,000.

Team · 1

Founder · CEO & Co-founder
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatients
Business model
B2B

Highlights

1 Patents

Tags

pediatricsseniorsautoimmune-diseasesbiotechnologycell-therapyrare-diseasespharma-companieschildrenmedical-technologies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)